Leveraging Homologous Recombination Deficiency via the Repositioned Prodrug CB1954
James L. Elia, Jarvis Hill, Collin D. Heer…·Ranjit S. Bindra
This paper identifies CB1954 as a selective therapy for BRCA2-deficient cancers by showing its activity in HRD cells and mechanism of action.